BCL-2 family antagonists for cancer therapy
- Author(s)
- Lessene, G; Czabotar, PE; Colman, PM;
- Details
- Publication Year 2008-12,Volume 7,Issue #12,Page 989-1000
- Journal Title
- NATURE REVIEWS DRUG DISCOVERY
- Publication Type
- Journal Article
- Abstract
- Overexpression of members of the BCL-2 family of pro-survival proteins is commonly associated with unfavourable pathogenesis in cancer. The convergence of cytotoxic stress signals on the extended BCL-2 protein family provides the biological rationale for directly targeting this family to induce apoptotic cell death. Recently, several compounds have been described that inhibit the interaction between BCL- 2 family members and their natural ligand, a helical peptide sequence known as the BH3 domain. Here, we review preclinical and clinical data on these compounds, and recommend four criteria that define antagonists of the BCL-2 protein family.
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- SMALL-MOLECULE INHIBITOR; PROTEIN-PROTEIN INTERACTIONS; ANTIAPOPTOTIC BCL-2-FAMILY PROTEINS; CHRONIC LYMPHOCYTIC-LEUKEMIA; STRUCTURE-BASED DESIGN; PROGRAMMED CELL-DEATH; BH3 MIMETIC ABT-737; PLATELET LIFE-SPAN; PHASE-I TRIAL; BH3-ONLY PROTEINS
- Publisher's Version
- https://doi.org/10.1038/nrd2658
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2008-12-01 12:00:00